Evidence map›Paper›PMID 40005214›Full record

ArticleMolecules (Basel, Switzerland)2025

Design, Synthesis and Biological Activity Study of γ-Aminobutyric Acid (GABA) Derivatives Containing Bridged Bicyclic Skeletons as BCAT1 Inhibitors.

Wen Luo, Zilu Pan, Xinyuan Zhu, Yan Li, Yong Li, Yudi Zhang, Jiamin Pan, Jian Ding, Hua Xie, Guilong Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wen LuoSchool of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Zilu PanShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Xinyuan ZhuZhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China.
Yan LiShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Yong LiSchool of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Yudi ZhangShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Jiamin PanSchool of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Jian DingShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Hua XieSchool of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Guilong ZhaoSchool of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.ORCID 0000-0001-8170-2909

Funding

Creative Research Group of Zhongshan City (Lingnan Pharmaceutical Research and Innovation team) CXTD2022011Guangdong Basic and Applied Basic Research Foundation 2023A1515012259High-level Innovative Research Institute, Department of Science and Technology of Guangdong Province 2021B0909050003National Natural Science Foundation of China 82273948Opening Foundation from State Key Laboratory of Drug Research SKLDR-2023-TT-01Special Funds of National Natural Science Foundation of China 82441046the Project of Shanghai Institute of Materia Medica, Chinese Academy of Sciences SIMM0120231001Zhongshan Municipal Natural Science Foundation 2023B2019
6 · The paper itself

Abstract

Branched-chain amino acid aminotransferases (BCATs), existing as the two isoforms BCAT1 and BCAT2, are responsible for the catabolism of branched-chain amino acids (BCAAs) and are highly upregulated and implicated in a diverse range of cancers. BCAT1 inhibitors represent a potential class of therapeutic agents for cancers; however, none have yet progressed to clinical development. Our earlier research identified

Indexed as

4-Aminobutyrate TransaminaseAntineoplastic AgentsDrug DesignEnzyme Inhibitorsgamma-Aminobutyric AcidCell Line, TumorCell ProliferationHumansMolecular StructureStructure-Activity RelationshipTransaminases4-Aminobutyrate TransaminaseAntineoplastic AgentsBCAT1 protein, humanEnzyme Inhibitorsgamma-Aminobutyric AcidTransaminasesamino acidBCAT1 inhibitorbicyclo[3.2.1]octanecancer resistanceGABAstructure–activity relationshipthird-generation EGFR TKI

Identifiers

PMID40005214
PMCPMC11858294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.